Drugs / CD4 CAR+CCR5 ZFN T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03617198 | Jul 2019 → Dec 2026 expected | HIV infectious disease | University of Pennsylvania | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD4 CAR+CCR5 ZFN T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03617198 ↗ |
| Action | Inhibit | “zinc finger nuclease-mediated disruption of the CCR5 gene” NCT03617198 ↗ |
| Modality | Cell therapy | “single infusion of autologous T cells genetically modified to express a CD4 chimeric antigen receptor” NCT03617198 ↗ |
| Target | CCR5 | “zinc finger nuclease-mediated disruption of the CCR5 gene” NCT03617198 ↗ |